Literature DB >> 28254873

Inter- and Intraobserver Agreement of 18F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis.

Hiroshi Ohira1,2, Brian Mc Ardle1, Robert A deKemp1, Pablo Nery1, Daniel Juneau1,3, Jennifer M Renaud1, Ran Klein1, Owen Clarkin1, Karen MacDonald1, Eugene Leung4, Girish Nair1, Rob Beanlands1, David Birnie5.   

Abstract

Recent studies have reported the usefulness of 18F-FDG PET in aiding with the diagnosis and management of patients with cardiac sarcoidosis (CS). However, image interpretation of 18F-FDG PET for CS is sometimes challenging. We sought to investigate the inter- and intraobserver agreement and explore factors that led to important discrepancies between readers.
Methods: We studied consecutive patients with no significant coronary artery disease who were referred for assessment of CS. Two experienced readers masked to clinical information, imaging reports, independently reviewed 18F-FDG PET/CT images. 18F-FDG PET/CT images were interpreted according to a predefined standard operating procedure, with cardiac 18F-FDG uptake patterns categorized into 5 patterns: none, focal, focal on diffuse, diffuse, and isolated lateral wall or basal uptake. Overall image assessment was classified as either consistent with active CS or not.
Results: One hundred scans were included from 71 patients. Of these, 46 underwent 18F-FDG PET/CT with a no-restriction diet (no-restriction group), and 54 underwent 18F-FDG PET/CT with a low-carbohydrate, high-fat and protein-permitted diet (low-carb group). There was agreement of the interpretation category in 74 of 100 scans. The κ-value of agreement among all 5 categories was 0.64, indicating moderate agreement. For overall clinical interpretation, there was agreement in 93 of 100 scans (κ = 0.85). When scans were divided into the preparation groups, there was a trend toward higher agreement in the low-carb group versus the no-restriction group (80% vs. 67%, P = 0.08). Regarding the overall clinical interpretation, there was also a trend toward greater agreement in the low-carb group versus the no-restriction group (96% vs. 89%, P = 0.08).
Conclusion: The interobserver agreement of cardiac 18F-FDG uptake image patterns was moderate. However, agreement was better regarding overall interpretation of CS. Detailed prescan dietary preparation seemed to improve interobserver agreement.
© 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  FDG-PET; cardiac sarcoidosis; inter-observer agreement

Mesh:

Substances:

Year:  2017        PMID: 28254873     DOI: 10.2967/jnumed.116.187203

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

2.  Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake.

Authors:  Osamu Manabe; Markus Kroenke; Tadao Aikawa; Atsuto Murayama; Masanao Naya; Atsuro Masuda; Noriko Oyama-Manabe; Kenji Hirata; Shiro Watanabe; Tohru Shiga; Chietsugu Katoh; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2017-12-14       Impact factor: 5.952

3.  Does simplified quantitative analysis of 18F-FDG PET in cardiac inflammatory disease work?

Authors:  R Nkoulou; H Zaidi
Journal:  J Nucl Cardiol       Date:  2018-01-17       Impact factor: 5.952

4.  Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis.

Authors:  Osamu Manabe; Hiroshi Ohira; Kenji Hirata; Souichiro Hayashi; Masanao Naya; Ichizo Tsujino; Tadao Aikawa; Kazuhiro Koyanagawa; Noriko Oyama-Manabe; Yuuki Tomiyama; Keiichi Magota; Keiichiro Yoshinaga; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-16       Impact factor: 9.236

5.  Test-retest repeatability and interobserver variation of healthy tissue metabolism using 18F-FDG PET/CT of the thorax among lung cancer patients.

Authors:  Afnan A Malaih; Joel T Dunn; Lotte Nygård; David G Kovacs; Flemming L Andersen; Sally F Barrington; Barbara M Fischer
Journal:  Nucl Med Commun       Date:  2022-05-01       Impact factor: 1.698

6.  Cardiac sarcoidosis: A long term follow up study.

Authors:  Patrice Cacoub; Catherine Chapelon-Abric; Matthieu Resche-Rigon; David Saadoun; Anne Claire Desbois; Lucie Biard
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

7.  FLT-PET for the assessment of systemic sarcoidosis including cardiac and CNS involvement: a prospective study with comparison to FDG-PET.

Authors:  Patrick Martineau; Matthieu Pelletier-Galarneau; Daniel Juneau; Eugene Leung; Pablo Nery; Rob deKemp; Rob Beanlands; David Birnie
Journal:  EJNMMI Res       Date:  2020-12-10       Impact factor: 3.138

8.  Machine learning techniques for arrhythmic risk stratification: a review of the literature.

Authors:  Cheuk To Chung; George Bazoukis; Sharen Lee; Ying Liu; Tong Liu; Konstantinos P Letsas; Antonis A Armoundas; Gary Tse
Journal:  Int J Arrhythmia       Date:  2022-04-01

9.  Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis.

Authors:  Hiroshi Ohira; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Akiko Hayashishita; Toshitaka Nakaya; Junichi Nakamura; Naoko Suzuki; Ayako Sugimoto; Sho Furuya; Satonori Tsuneta; Taku Watanabe; Ichizo Tsujino; Satoshi Konno
Journal:  ERJ Open Res       Date:  2022-05-09

Review 10.  Advances in Diagnostic Imaging for Cardiac Sarcoidosis.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Tadao Aikawa; Satonori Tsuneta; Nagara Tamaki
Journal:  J Clin Med       Date:  2021-12-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.